Here is a fact worth sitting with. The warnings printed on cigarette packs sold in the United States today are still the four rotating text warnings Congress mandated in the Comprehensive Smoking Education Act of 1984: lung cancer, heart disease, emphysema, pregnancy complications, and carbon monoxide. When the U.S. Food and Drug Administration issued its final rule in March 2020 adopting eleven new graphic warnings, it added conditions the public had never been told about on a pack — type 2 diabetes, age-related macular degeneration, bladder cancer, cataracts, amputation. It did not add rheumatoid arthritis.
Those graphic warnings have still never reached a pack. In January 2025, U.S. District Judge J. Campbell Barker of the Eastern District of Texas sided with R.J. Reynolds and other manufacturers, holding that the FDA had exceeded its authority by requiring eleven warnings when the Family Smoking Prevention and Tobacco Control Act of 2009 specified nine, and he postponed the rule's effective date pending further litigation — blocking the enforcement date that would otherwise have arrived in February 2026. It was the second time the same judge had halted the rule. So the practical situation today is this: the warnings actually printed on American cigarette packs are the four written in 1984, and even the expanded list the government fought for over a decade to add — the list that still says nothing about rheumatoid arthritis — is not on them.
Yet six years before that rule, in its landmark 2014 report The Health Consequences of Smoking—50 Years of Progress, the U.S. Surgeon General concluded that the evidence is sufficient to infer a causal relationship between cigarette smoking and rheumatoid arthritis — the same standard of proof the report applies to lung cancer and stroke. A person can read every warning the federal government has ever required on a cigarette pack, and every warning it has proposed, and never learn that the product is a recognized cause of a disabling autoimmune disease that will not go away.
This piece continues the firm's series on the harms cigarettes cause that almost no one connects to smoking — the cancers far from the lungs, the vision loss, the type 2 diabetes. Rheumatoid arthritis belongs in that company, and it has a feature none of the others do: the biology that links it to smoking is so specific that the proof is often already sitting in the patient's own blood work. Below: what rheumatoid arthritis is and how it differs from ordinary arthritis, why it sits on the Surgeon General's list, the citrullination pathway that explains the link, how large the risk is, how smoking blunts the treatments, the “it's autoimmune, it's genetic” defense, and how a claim of this kind fits the tobacco-liability framework.
What Rheumatoid Arthritis Is — and What It Is Not
Rheumatoid arthritis is an autoimmune disease, not a wear-and-tear condition. The immune system attacks the synovium, the lining of the joints, producing chronic inflammation that swells and stiffens joints and, over years, erodes cartilage and bone. It typically strikes the small joints of the hands, wrists, and feet, usually on both sides of the body at once, and it is a whole-body illness: it can inflame the lungs, the eyes, and the blood vessels, and it raises cardiovascular risk. According to the Centers for Disease Control and Prevention and the Arthritis Foundation, it affects well over a million American adults, and it is more common in women.
This is the distinction that matters most to readers, because it is the one most often confused. Osteoarthritis is mechanical — cartilage wearing down with age and use. Rheumatoid arthritis is immunological — the body's own defenses turned on its joints, driven by a process that begins before the first swollen knuckle appears. It is diagnosed by a rheumatologist using clinical examination, imaging, inflammatory markers, and blood tests for rheumatoid factor and anti-cyclic citrullinated peptide antibodies (anti-CCP). Those last two tests turn out to matter enormously to the smoking question. When this article refers to rheumatoid arthritis, it does not mean osteoarthritis.
Why Rheumatoid Arthritis Is on the Surgeon General’s Smoking List
This is not a plaintiff's theory. It is the conclusion of the government's highest scientific authority on tobacco. The 2014 Surgeon General's report added rheumatoid arthritis to the list of diseases for which the evidence is sufficient to infer a causal relationship with cigarette smoking, after more than twenty-five years of accumulating epidemiology.
What gives the finding particular weight is what the same report declined to conclude. The Surgeon General examined systemic lupus erythematosus — another autoimmune disease often discussed alongside rheumatoid arthritis — and found the evidence not sufficient to infer causation. The report drew a line, and rheumatoid arthritis fell on the causal side of it. That is the mark of a careful evidentiary judgment rather than a blanket condemnation, and it is why the conclusion carries real force in litigation. The report went further still, noting that cigarette smoking can reduce the effectiveness of tumor necrosis factor-alpha inhibitors — a mainstay of modern rheumatoid arthritis treatment.
The Biology: How Cigarette Smoke Teaches the Immune System to Attack Joints
Most smoking diseases are explained by carcinogens damaging DNA or by smoke inflaming and scarring tissue. Rheumatoid arthritis works differently, and the mechanism is unusually well mapped:
- Citrullination in the lungs. Enzymes called peptidylarginine deiminases convert the amino acid arginine in the body's own proteins into citrulline. Cigarette smoke drives this process in lung tissue, generating a supply of altered, citrullinated proteins.
- An immune response to the body's own altered proteins. In genetically susceptible people, the immune system fails to recognize these modified proteins as self and produces anti-citrullinated protein antibodies — measured clinically as anti-CCP.
- The genetic partner. Susceptibility is concentrated in people carrying HLA-DRB1 “shared epitope” alleles. Research in several European and Asian populations has documented an interaction between smoking and these alleles in the development of antibody-positive rheumatoid arthritis substantially greater than either factor alone, though the interaction has not been replicated uniformly in every North American cohort.
- From antibodies to joints. Those antibodies can be present in the blood for years before joint symptoms begin. The disease that eventually surfaces in the hands and feet began upstream — in the lungs, where the smoke was.
The consequence is a signature. Because smoking acts through the citrullination pathway, its association is strongest with seropositive disease — rheumatoid arthritis with rheumatoid factor or anti-CCP antibodies present. The dose-response meta-analysis published in Arthritis Research & Therapy in 2014 found the risk substantially higher among rheumatoid-factor-positive cases (relative risk 2.47) than among rheumatoid-factor-negative cases (1.58) when comparing the heaviest with the lightest smoking exposure. Smoking is not associated with rheumatoid arthritis in general so much as with the specific antibody-driven form the science predicts it should cause — which is precisely the kind of coherence between mechanism and epidemiology that separates a real causal link from a coincidence.
How Big Is the Risk?
Substantial and dose-dependent. The meta-analytic evidence the Surgeon General relied on found an elevated risk of rheumatoid arthritis among people who had ever smoked (relative risk 1.4), among current smokers (1.35), and among former smokers (1.25), compared with people who never smoked. The dose-response picture is sharper still:
- 1 to 10 pack-years: roughly a 26 percent higher risk of rheumatoid arthritis than never-smokers (relative risk 1.26).
- 21 to 30 pack-years: risk roughly doubled (relative risk 1.94).
- More than 40 pack-years: relative risk 2.07 — the curve plateaus after about 20 pack-years rather than climbing without limit, a pattern consistent with a threshold of exposure beyond which the immune process is fully triggered.
- Risk persists after quitting. Former smokers still carry elevated risk, and the rheumatology literature describes the excess declining only slowly over many years — unlike some smoking harms that fall away quickly.
A doubling of risk in a lifelong, joint-destroying disease is not a statistical footnote. Where a longtime smoker develops seropositive rheumatoid arthritis, cigarettes belong on the list of causes that genuinely help explain it.
A Distinctive Fact: Smoking Also Makes the Disease Harder to Treat
Most diseases in this series are injuries a smoker either has or does not have. Rheumatoid arthritis, like type 2 diabetes, plays a double role: smoking raises the risk of developing it and worsens it once it arrives.
Longitudinal research has found smoking associated with higher disease activity in rheumatoid arthritis even after controlling for factors that change over time. Smokers are more likely to have erosive joint damage and extra-articular complications, including rheumatoid lung disease. And as the 2014 Surgeon General's report itself noted, smoking can reduce the effectiveness of TNF-alpha inhibitors — meaning the same product that helped cause the disease also undercuts the biologic therapies used to control it. A smoker with rheumatoid arthritis often faces a more aggressive illness and a harder path to remission than a non-smoker with the same diagnosis, which speaks directly to the extent of the harm.
The Defense: “It’s an Autoimmune Disease. It’s Genetic. Not Our Cigarettes.”
Expect exactly this argument, and expect it to sound reasonable. Rheumatoid arthritis is autoimmune. It does run in families. Genetics are a real and significant contributor. None of that ends a case.
The answer is in the science the defense would have to disown. Rheumatoid arthritis research does not treat smoking and the HLA-DRB1 shared epitope as competing explanations — it treats them as partners in the same causal pathway. The genes create susceptibility; the smoke supplies the citrullinated proteins the susceptible immune system misreads. In the populations where the interaction has been measured, the two together produce far more antibody-positive disease than either would alone. That is why millions of people carry the shared epitope and never develop rheumatoid arthritis, and why the risk climbs steadily with pack-years in those who do.
In product-liability law the framework is the same one the firm applies in its lung cancer matters: a manufacturer whose product was a substantial contributing factor to an injury does not escape responsibility by naming other factors that also contributed. Where a person's genes and thirty years of cigarettes acted on the same immune system, the sound question is not which one caused the arthritis but whether the cigarettes were a substantial factor in causing it. This mirrors the “it was just your age and your genes” deflection the firm answers in its macular degeneration guide and the “it was your weight and your diet” deflection in its diabetes guide: a second cause is a fact to be accounted for, not a defense that clears the product.
The Legal Framework
Smoking-related rheumatoid arthritis matters proceed on the same liability theories as other smoking-disease cases against the tobacco industry:
- Negligent design, manufacture, and marketing of cigarettes.
- Strict product liability for an unreasonably dangerous product.
- Failure to warn about the full range of harms smoking causes — a theory with unusual force here, because rheumatoid arthritis has never appeared on a required warning, not in 1984 and not in the FDA's 2020 rule.
- Fraud and misrepresentation about the safety and addictiveness of the products.
- Civil conspiracy among manufacturers to suppress and distort health research.
The internal industry records unearthed in prior tobacco litigation — the documents showing what the companies knew and when — remain central evidence. Our companion piece on how tobacco companies hid the truth walks through that record. Alex Alvarez, the firm's Managing Partner and a Board Certified Civil Trial Lawyer (The Florida Bar), brings that documentary history together with each client's own smoking and medical records to build the causation case an autoimmune claim requires, and to meet the genetics argument described above.
Separating a genuine smoking-driven case from ordinary rheumatoid arthritis is medical work as much as legal work, and it is where the firm's Medical-Legal Expert earns his place. Herb Borroto, M.D., J.D., who holds both a medical degree and a law degree, reads the rheumatology records the way a clinician does and the way a lawyer must: the anti-CCP and rheumatoid factor results, the inflammatory markers, the erosion seen on imaging, the response or non-response to biologic therapy, and the smoking history measured in pack-years, all together. A purely legal review has no reason to know that an anti-CCP titer is the fingerprint of the citrullination pathway; a purely clinical review has no reason to connect it to liability. The serology that a rheumatologist ordered years ago, for entirely clinical reasons, is often the single most important document in the file.
What a Rheumatoid Arthritis Case Needs
- Documentation of the diagnosis — the rheumatology records confirming rheumatoid arthritis rather than osteoarthritis or another inflammatory condition.
- The serology: anti-CCP and rheumatoid factor results, and inflammatory markers, establishing whether the disease is seropositive.
- A substantial smoking history, measured in pack-years, spanning the years before onset that the science implicates.
- The timeline of onset and progression — joint erosion on imaging, extra-articular involvement, and the record of which therapies were tried and how well they worked.
- Brand identification — which cigarettes were smoked, and for how long.
- Causation testimony from an appropriate expert familiar with the smoking–rheumatoid arthritis literature.
- Documentation of the impact on daily life — the pain, the loss of hand function and mobility, the medication burden, and the lost work that living with the disease imposes.
Unlike many of the cancers in this series, a rheumatoid arthritis matter is usually brought by the living, injured smoker rather than as a wrongful death claim, because the disease is chronic and disabling rather than rapidly fatal. The unglamorous paperwork behind these elements is what carries the case. Our guide to smoking history documentation covers the records that build or break a tobacco claim.
The Jurisdictions We Serve
The Alvarez Law Firm represents smokers and families in Hawaii, Illinois, Nevada, Oregon, Pennsylvania, and the U.S. Virgin Islands. Each of those jurisdictions has its own filing deadlines, its own substantive law on tobacco product liability, and its own version of the discovery rule — how long after a diagnosis a claim must be filed. Those deadlines are unforgiving and easy to overlook while a person is absorbed in managing a new chronic illness, so talk to counsel licensed in the relevant state about how they apply to your situation. Waiting can foreclose options that were available earlier.
Frequently Asked Questions
Does smoking cause rheumatoid arthritis?
Yes. In its 2014 report, The Health Consequences of Smoking—50 Years of Progress, the U.S. Surgeon General concluded that the evidence is sufficient to infer a causal relationship between cigarette smoking and rheumatoid arthritis. That is the same standard of proof the report applies to lung cancer and stroke. The meta-analysis the report relied on found roughly a 40 percent higher risk of rheumatoid arthritis in people who had ever smoked compared with people who never smoked, and a separate dose-response meta-analysis published in Arthritis Research & Therapy found the risk roughly doubled at more than 20 pack-years. Because rheumatoid arthritis also has a strong genetic component, a longtime smoker who has been diagnosed should have the full rheumatology record reviewed by counsel.
Is rheumatoid arthritis on the cigarette warning label?
No. The warnings that appear on cigarette packs sold in the United States are the four rotating text warnings Congress mandated in the Comprehensive Smoking Education Act of 1984, which name lung cancer, heart disease, emphysema, pregnancy complications, and carbon monoxide. Rheumatoid arthritis is not among them. It is also absent from the eleven new graphic warnings the U.S. Food and Drug Administration adopted by final rule in March 2020 — a set that does add warnings for type 2 diabetes, age-related macular degeneration, bladder cancer, cataracts, and other conditions, but says nothing about rheumatoid arthritis. A person could read every warning the federal government has ever required on a cigarette pack and never learn that the product is a recognized cause of a disabling, lifelong autoimmune disease.
How do you prove smoking caused rheumatoid arthritis and not genetics?
You do not have to rule genetics out. Rheumatoid arthritis research describes smoking and the HLA-DRB1 “shared epitope” genes as acting together rather than as alternatives: smoking drives citrullination of proteins in the lungs, and in genetically susceptible people the immune system responds by producing anti-citrullinated protein antibodies, measured clinically as anti-CCP. That is why the smoking association is strongest for seropositive disease — the dose-response meta-analysis found the risk was substantially higher among rheumatoid-factor-positive cases than rheumatoid-factor-negative ones. In product-liability law, a manufacturer whose product was a substantial contributing factor to an injury does not escape responsibility because another factor also contributed. The anti-CCP and rheumatoid factor results already in the medical chart, read against a smoking history measured in pack-years, are often the most important evidence in these cases.
If You or a Family Member Has Been Diagnosed
If you have a substantial smoking history and have been diagnosed with rheumatoid arthritis — particularly if your records show a positive anti-CCP or rheumatoid factor result — a free, confidential case review is the right next step. The same conversation that produces a viable lung cancer case can produce a viable rheumatoid arthritis case, even though the disease appears on no warning label.
- Start at the lungs, where most smoking cases begin: Lung Cancer and Your Legal Rights and COPD After Years of Smoking.
- Read about the other diseases the 2014 Surgeon General's report added: Type 2 Diabetes and Macular Degeneration.
- Learn how the industry concealed the harms: How Tobacco Companies Hid the Truth.
Free case review. No fees unless we recover compensation for you.
Sources
- U.S. Department of Health and Human Services, Office of the Surgeon General — The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General (2014), which concluded that the evidence is sufficient to infer a causal relationship between cigarette smoking and rheumatoid arthritis, found the evidence not sufficient for systemic lupus erythematosus, and noted that smoking can reduce the effectiveness of TNF-alpha inhibitors. hhs.gov/surgeongeneral
- Di Giuseppe et al. — "Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis," Arthritis Research & Therapy (2014), reporting a relative risk of 1.26 at 1–10 pack-years, 1.94 at 21–30 pack-years, and 2.47 for rheumatoid-factor-positive versus 1.58 for rheumatoid-factor-negative disease. arthritis-research.biomedcentral.com
- U.S. Food and Drug Administration — "Tobacco Products; Required Warnings for Cigarette Packages and Advertisements," final rule, 85 Fed. Reg. 15638 (March 18, 2020), specifying the eleven new textual warning statements and accompanying images. federalregister.gov
- Comprehensive Smoking Education Act of 1984, 15 U.S.C. § 1333 — the four rotating Surgeon General's warnings required on cigarette packages. uscode.house.gov
- Klareskog et al. — research on smoking, HLA-DRB1 shared epitope alleles, and anti-citrullinated protein antibody formation in rheumatoid arthritis, published in the peer-reviewed rheumatology literature and indexed by the National Library of Medicine. pubmed.ncbi.nlm.nih.gov
- R.J. Reynolds Tobacco Co. v. U.S. Food & Drug Administration (E.D. Tex.) — January 2025 ruling by U.S. District Judge J. Campbell Barker holding that the FDA exceeded the authority granted by the Family Smoking Prevention and Tobacco Control Act of 2009 in adopting eleven graphic warnings, and postponing the rule's effective date pending further litigation, which blocked the February 2026 enforcement date. publichealthlawcenter.org
- Centers for Disease Control and Prevention — public health information on rheumatoid arthritis, its prevalence among U.S. adults, and smoking as a modifiable risk factor. cdc.gov/arthritis
- Arthritis Foundation — patient education on rheumatoid arthritis, its distinction from osteoarthritis, and the role of smoking in disease risk and severity. arthritis.org